| Autor: |
Frew, Lesley C, Leung, Steve KW |
| Předmět: |
|
| Zdroj: |
International Journal of Urological Nursing; Jul2015, Vol. 9 Issue 2, p114-118, 5p, 2 Charts, 2 Graphs |
| Abstrakt: |
ABSTRACT Injectable hormone therapy is a key element of treatment for many patients with prostate cancer. In the UK, it is typically administered in primary care. In 2003, National Health Service ( NHS) Fife rolled out an innovative service for these patients, in which responsibility was moved from primary care to a specialist nurse-led service in secondary care. The initial rationale was based on cost savings, but a significant number of other advantages have subsequently been demonstrated. These include a simpler patient journey, improved continuity of care and reduced use of consultant time. Standards of care have also improved, with fewer missed appointments, better provision of patient support and rapid access to specialist physician care when needed. An audit of 377 of 542 patients currently treated within the service has provided supportive evidence for many of these advantages. The Fife service offers a cost-effective model for locally provided nurse-led care that could be applied to hormone therapy services for prostate cancer elsewhere in the UK, and to services for other cancers with large numbers of patients requiring long-term management. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text